Does microdosing psychedelics work?

Numbers match the citations in the article. A working link isn't proof that a page supports a claim; check the quoted passage and date.

1. 1

   Self-blinding citizen science to explore psychedelic microdosing

   eLife (Szigeti et al.)Published Mar 1, 2021Checked Sep 30, 2026

   “Microdosing is the practice of regularly using low doses of psychedelic drugs. Anecdotal reports suggest that microdosing enhances well-being and cognition; however, such accounts are potentially biased by the placebo effect. This study used a 'self-blinding' citizen science initiative, where participants were given online instructions on how to incorporate placebo control into their microdosing routine without clinical supervision. The study was completed by 191 participants, making it the largest placebo-controlled trial on psychedelics to-date. All psychological outcomes improved significantly from baseline to after the 4 weeks long dose period for the microdose group; however, the placebo group also improved and no significant between-groups differences were observed. Acute (emotional state, drug intensity, mood, energy, and creativity) and post-acute (anxiety) scales showed small, but significant microdose vs. placebo differences; however, these results can be explained by participants breaking blind. The findings suggest that anecdotal benefits of microdosing can be explained by the placebo effect.”

2. 2

   Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

   Translational Psychiatry (Cavanna et al.)Published Aug 2, 2022Checked Sep 30, 2026

   “Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.”

3. 3

   Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study

   European Neuropsychopharmacology (Hutten et al.)Published Oct 17, 2020Checked Sep 30, 2026

   “A placebo-controlled within-subject study including 24 healthy participants, was conducted to assess the acute effects of three LSD doses (5, 10, and 20 mcg) on measures of cognition, mood, and subjective experience, up until 6 h after administration. Cognition and subjective experience were assessed using the Psychomotor Vigilance Task, Digit Symbol Substitution Test, Cognitive Control Task, Profile of Mood States, and 5-Dimensional Altered States of Consciousness rating scale. LSD showed positive effects in the majority of observations by increasing positive mood (20 mcg), friendliness (5, 20 mcg), arousal (5 mcg), and decreasing attentional lapses (5, 20 mcg). Negative effects manifested as an increase in confusion (20 mcg) and anxiety (5, 20 mcg). Psychedelic-induced changes in waking consciousness were also present (10, 20 mcg). Overall, the present study demonstrated selective, beneficial effects of low doses of LSD on mood and cognition in the majority of observations. The minimal LSD dose at which subjective and performance effects are notable is 5 mcg and the most apparent effects were visible after 20 mcg.”

4. 4

   Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis.

   Neuroscience and biobehavioral reviews (Pinhas et al.)Published Nov 26, 2025Checked Oct 4, 2026

   “Results show a significant decrease in cognitive control, with no detectable effects on other cognitive domains or in general. Neither substance type (psilocybin or LSD), dosage (0.1-0.5 g psilocybin; 6.5-20 µg LSD), nor microdosing duration (1-42 days) emerged as significant moderators. Assessment timing (on- vs. off-drug) likewise did not moderate the effects. These findings suggest that microdosing may disrupt top-down cognitive control processes, aligning with cognitive and neural models of how classical psychedelics alter information processing in the brain to reduce rigidity and enable more fluid states of consciousness. However, better distinguishing between on-drug and off-drug effects is essential for clarifying whether microdosing exerts only transient pharmacological influences or promotes lasting cognitive change. Given the methodological heterogeneity across studies, future research using standardized protocols and mechanistic approaches is needed to fully characterize the cognitive and neural effects of microdosing classical psychedelics.”

5. 5

   Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

   Scientific Reports (Kaertner et al.)Published Jan 21, 2021Checked Sep 30, 2026

   “Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic timepoints, spanning a core four-week test period. Eighty-one participants completed the primary study endpoint. Results revealed increased self-reported psychological well-being, emotional stability and reductions in state anxiety and depressive symptoms at the four-week primary endpoint, plus increases in psychological resilience, social connectedness, agreeableness, nature relatedness and aspects of psychological flexibility. However, positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response. This study highlights a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.”

6. 6

   A systematic study of microdosing psychedelics

   PLoS ONE (Polito & Stevenson)Published Feb 6, 2019Checked Sep 30, 2026

   “Analyses of daily ratings revealed a general increase in reported psychological functioning across all measures on dosing days but limited evidence of residual effects on following days. Analyses of pre and post study measures revealed reductions in reported levels of depression and stress; lower levels of distractibility; increased absorption; and increased neuroticism. To better understand these findings, in Study Two we investigated pre-existing beliefs and expectations about the effects of microdosing in a sample of 263 naïve and experienced microdosers, so as to gauge expectancy bias. All participants believed that microdosing would have large and wide-ranging benefits in contrast to the limited outcomes reported by actual microdosers. Notably, the effects believed most likely to change were unrelated to the observed pattern of reported outcomes. The current results suggest that dose controlled empirical research on the impacts of microdosing on mental health and attentional capabilities are needed.”

7. 7

   The subtle science: a systematic review of psilocybin magic mushroom and truffle microdosing.

   Frontiers in psychiatry (Page et al.)Published Aug 19, 2026Checked Oct 4, 2026

   “However, the majority of evidence had at least some concerns for risk of bias or was qualitative and used a variety of self-reported outcome measures. Approximately 86% of microdoser motivations were non-medical and only 14% were related to medical diagnoses, mostly for mental health improvements. Extreme heterogeneity was identified across dosing protocols and preparations. The majority of studies did not report adverse events but for those reported, they were mostly mild. All but four studies declared no conflicts of interest and four did not disclose funding sources.DiscussionThe certainty of the evidence is low, and a causal effect of microdosing cannot be inferred. Future research should prioritize well-powered randomized controlled trials with standardized and substance-specific dosing protocols to determine causal relationships between microdosing MM or truffles and health outcomes. Mandatory reporting of adverse events and funding sources should be implemented to build the safety profile of microdosing MM and truffles and ensure transparency for potential conflicts of interest.Sytematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023428107.”

8. 8

   Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults.

   American journal of preventive medicine (Yang et al.)Published May 4, 2026Checked Oct 4, 2026

   “Cannabis (41.2%; 95% CI=33.3, 49.5) was primarily microdosed for medical purposes (e.g., to manage pain), whereas psilocybin (66.6%; 95% CI=56.9, 75.1), LSD (59.2%; 95% CI=46.5, 70.8), and MDMA (86.0%; 95% CI=68.8, 94.5) were more commonly microdosed for recreational purposes (e.g., to get less high). Across all substances, lifetime microdose use was more prevalent among respondents reporting poorer mental health and among those residing in jurisdictions that permitted recreational cannabis use and had decriminalized psychedelic possession.ConclusionsDespite cannabis, psilocybin, LSD, and MDMA remaining illegal at the federal level, a considerable number of U.S. adults reported having microdosed these substances in their lifetime. Microdosing was associated with poorer mental health and was more common among respondents who lived in environments with fewer restrictions on the use of cannabis and psychedelics. As policy reforms continue to expand, the prevalence of microdosing may increase, making ongoing surveillance essential for evidence-based public health responses.”

9. 9

   Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

   Journal of Psychopharmacology (Kuypers et al.)Published Jul 14, 2019Checked Sep 30, 2026

   “However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is. This critique paper is designed to address questions that need to be answered by future scientific studies and to offer guidelines for these studies. APPROACH: Owing to its proximity for a possible approval in clinical use and short-lasting pharmacokinetics, our focus is predominantly on psilocybin. Psilocybin is allegedly, next to lysergic acid diethylamide (LSD), one of the two most frequently used psychedelics to microdose. Where relevant and available, data for other psychedelic drugs are also mentioned. It is concluded that while most anecdotal reports focus on the positive experiences with microdosing, future research should also focus on potential risks of (multiple) administrations of a psychedelic in low doses. To that end, (pre)clinical studies including biological (e.g. heart rate, receptor turnover and occupancy) as well as cognitive (e.g. memory, attention) parameters have to be conducted and will shed light on the potential negative consequences microdosing could have.”